Sign up for ICER's Weekly View Newsletter

 

Weekly View


May 8, 2026

From the desk of Priya Ranade

Good morning, everyone.

The Health Economics Methods Advisory (HEMA) announced a new research topic this week: an assessment of approaches to evaluating, presenting, and communicating uncertainty in economic evaluations.


Mark Sculpher, PhD, Chair of the HEMA Working Group, explained: “Uncertainties in economic evaluation can come from a range of sources, including small sample sizes, limitations in the available evidence, and assumptions used in the modeling. There are both established tools and new methods for quantifying these uncertainties; our goal is not only to review those methods, but also to recommend the best ways to use those tools to make better decisions about new medicines.”

 

HEMA plans to publish the final report in the first half of 2027. We look forward to learning more!

 

(Separately, on May 14th, ICER will host a virtual public meeting to discuss oveporexton, a treatment for narcolepsy type 1. An independent appraisal committee will review the findings of ICER's Evidence Report, hear further testimony from stakeholders, and deliberate on the treatment’s comparative clinical effectiveness, benefits beyond health, and long-term value for money. Register here.)

Let's see what else happened this week...

 

ICER in the News

 

Institute for Clinical and Economic Review Publishes Protocol for Annual Launch Price and Access Report

This week, ICER published a protocol for our second annual “Launch Price and Access Report." This protocol was developed with input from a multi-stakeholder working group* consisting of patient and consumer advocates, clinicians, policy experts, payers, and life science companies. 


ICER is committed to using the most accurate pricing information in our work, so we have also issued a call for manufacturers to provide pricing information. Manufacturers of any drug in scope approved between 2022 to 2025 may submit annual list and net price data at launch through our manufacturer submission survey. Submissions must be received by 5 PM ET on June 1, 2026. Data submitted by manufacturers and deemed reliable may be used publicly in the report and may replace previously used estimates of net price.

 
Pharmaceutical News

MUST READS

White House says Trump's deals with pharmaceutical companies offer billions in savings

The Associated Press

White House economists estimate that President Donald Trump's deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save billions over the next 10 years.


The analysis obtained by The Associated Press includes the first economy-wide projections behind a policy at the core of Trump's pitch to voters going into November's midterm elections for control of the House and Senate. Democratic lawmakers have been doubtful about the savings claimed by Trump and these new numbers are likely to trigger additional questions about the data.

A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know

KFF Health News

Starting in July, Medicare beneficiaries may be able to get a GLP-1 prescription for weight loss for $50 a month. It’s a notable shift for Medicare, which has long been barred from covering weight loss treatments.

 

The initiative, announced by the Centers for Medicare & Medicaid Services, is a short-term pilot program known as the Medicare GLP-1 Bridge. It will run from July 1, 2026, through Dec. 31, 2027. It’s meant to “bridge” the gap before a longer-term program that might — or might not — begin in 2028.The pilot program will offer coverage for the following GLP-1 medications approved for weight loss: the pill and injectable formulations of Wegovy, the KwikPen formulation of Zepbound, and the Foundayo pill.

UnitedHealth to Make It Easier for Patients to Get a Range of Procedures

The Wall Street Journal

UnitedHealth Group plans to stop requiring doctors to get approvals for an array of procedures, tests and services, cutting back on a process that has long been detested by physicians and patients. UnitedHealth, parent of the biggest U.S. health insurer, said the changes will slash the number of reviews by nearly a third starting later this year. Doctors have long complained about the paperwork they must complete to get insurers’ permission for care, which can lead to delays and denials.


UnitedHealthcare will stop requiring signoffs for tests including echocardiograms, some chiropractic care and certain outpatient surgeries. Also on the list is some outpatient therapy.

Medicaid’s GENEROUS Most-Favored-Nation Pricing Model — Promise and Limitations

The New England Journal of Medicine

Researchers from Harvard, Washington University in St. Louis, UPenn, and Cornell reflected on the GENEROUS program, which is a pilot program to introduce the Trump administration’s most-favored nation policies to Medicaid:

 

“The GENEROUS program can make a constructive contribution by building federal infrastructure for negotiating coverage criteria, sharing data, and supporting states that lack the capacity to de­velop new payment arrangements for Medicaid. To realize that po­tential, policymakers could treat international reference pricing as a transitional tool rather than the defining feature of the model and could eventually give CMS and states more latitude to negotiate prices and contracts on the basis of U.S. evidence and values. Framed in such a way, GENEROUS could become a vehicle for more flexible, value-oriented Medicaid drug purchasing, rather than a commitment to a narrow form of international benchmarking.”

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 6/8: Narcolepsy -- Final Evidence Report
  • 6/11: Covid-19 -- Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email